CANADIAN CANCER TRIALS GROUP BRAIN DISEASE SITE COMMITTEE MEETING AGENDA

OPEN SESSION Venue: Carlyle Room Date: Saturday, April 30th, 2016 Time: 9:00 a.m. – 12:00 p.m. Chair: Dr. Warren Mason

9:00 am Welcome and Introductions

Completed Studies

- 9:00 am **CE.5 (EORTC 22033-26033):** Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study – manuscript status **W. Mason**
- 9:05 am **CE.6:** A Randomized Phase III Study of Temozolomide a Short- Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Gliobalstoma Multiforme in Elderly Patients **J. Perry & N. Laperriere**

Trials Closed to Accrual Pending Analysis

- 9:20 am CEC.1 (EORTC 26053_22054): Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial-ASCO abstract W. Mason & C. O'Callaghan
- 9:25 am CEC.3 (NCCTG N107C): A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease D. Roberge

Actively Accruing Trials

9:30 am **CEC.6 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

W. Mason & C. O'Callaghan

9:40 am IND.222: A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression W. Mason

Approved Trials Pending Activation

- 9:50 am CEC.5 (ALLIANCE 221208): Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases C. Chung
- 10:00 am COFFEE BREAK

New Trials/Concepts for Discussion

- 10: 15 am A randomized phase II trial of Toca511 with Toca FC for patients with newly diagnosed GBM receiving RT with Temozolomide A.Das
 10:45 am A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases D. Roberge
- 11:15 amIdentifying Viable Therapeutic Targets of GBM Metabolism Through A Drug Screen:
A reality for clinical trial proposalG. Zadeh

Miscellaneous

11:45 amTerry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM Project
Status ReportW. Mason

M. Pitz

- 11:55 am Report from IND Committee
- 12:00 pm Closing Remarks